Insider Selling: Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) CEO Sells $15,684.90 in Stock

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) CEO Vininder Singh sold 10,670 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $1.47, for a total value of $15,684.90. Following the completion of the transaction, the chief executive officer now directly owns 2,504,197 shares in the company, valued at $3,681,169.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Vininder Singh also recently made the following trade(s):

• On Friday, July 5th, Vininder Singh sold 7,095 shares of Bullfrog AI stock. The shares were sold at an average price of $1.58, for a total value of $11,210.10.

Bullfrog AI Stock Performance

Bullfrog AI stock opened at $2.20 on Friday. Bullfrog AI Holdings, Inc. has a one year low of $1.43 and a one year high of $8.35. The stock’s 50 day moving average price is $2.46 and its 200 day moving average price is $3.34. The firm has a market capitalization of $17.27 million, a PE ratio of -2.50 and a beta of 0.11.

Bullfrog AI (NASDAQ:BFRG) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.26) earnings per share for the quarter.

Institutional Trading of Bullfrog AI

A hedge fund recently bought a new stake in Bullfrog AI stock. Fortem Financial Group LLC purchased a new stake in Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 53,300 shares of the company’s stock, valued at approximately $171,000. Fortem Financial Group LLC owned about 0.68% of Bullfrog AI as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.96% of the company’s stock.

About Bullfrog AI

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.